ARPA-H announced the teams for its THRIVE program, committing up to $160 million over five years to accelerate bespoke in vivo precision genetic medicines for rare genetic pediatric diseases. The initiative aims to speed solutions across multiple technological approaches, trial designs, and deployment models. THRIVE’s structure signals a focus on translational bottlenecks—particularly the path from preclinical proof to clinical implementation for rare targets where standard development economics are challenging. The program is positioned to support a spectrum of gene-editing and delivery strategies rather than a single modality. For biotech working in rare disease therapeutics, ARPA-H’s funding adds another downstream catalyst for platform maturation, clinical readiness, and potential partnerships with delivery and manufacturing specialists.